BRPI0511054A - uso de dipiridamola para o tratamento de resistência a inibidores plaquetários - Google Patents
uso de dipiridamola para o tratamento de resistência a inibidores plaquetáriosInfo
- Publication number
- BRPI0511054A BRPI0511054A BRPI0511054-8A BRPI0511054A BRPI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A BR PI0511054 A BRPI0511054 A BR PI0511054A
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- resistance
- treatment
- platelet
- dipyridamole
- Prior art date
Links
- 239000000106 platelet aggregation inhibitor Substances 0.000 title abstract 5
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960002768 dipyridamole Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 abstract 5
- 229940123583 Factor Xa inhibitor Drugs 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 108090000672 Annexin A5 Proteins 0.000 abstract 1
- 102000004121 Annexin A5 Human genes 0.000 abstract 1
- 229940123900 Direct thrombin inhibitor Drugs 0.000 abstract 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
- 108090000190 Thrombin Proteins 0.000 abstract 1
- 229940122388 Thrombin inhibitor Drugs 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 abstract 1
- 229960003856 argatroban Drugs 0.000 abstract 1
- 229960001500 bivalirudin Drugs 0.000 abstract 1
- 108010055460 bivalirudin Proteins 0.000 abstract 1
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 abstract 1
- -1 bivalrudine Chemical compound 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 239000003055 low molecular weight heparin Substances 0.000 abstract 1
- 229940127215 low-molecular weight heparin Drugs 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003868 thrombin inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
USO DE DIPIRIDAMOLA PARA O TRATAMENTO DE RESISTêNCIA A INIBIDORES PLAQUETáRIOS. A presente invenção refere-se a um método de tratamento de resistência a inibidores plaquetários, isto é, um método para superar a resistência de tratamento com inibidores plaquetários, o referido método compreendendo administração de uma quantidade terapeuticamente eficaz de dipiridamola em combinação com um inibidor plaquetário e, opcionalmente, em combinação com um terceiro componente antitrombótico, tal como inibidores diretos de trombina, inibidores de fator Xa, inibidores combinados de trombina/fator Xa, heparina, heparina de baixo peso molecular, argatroban, bivalrudina, hirulog ou poliglicanas a um paciente que precisa do mesmo. A invenção ainda se refere ao uso de dipiridamola para a fabricação de uma composição farmacêutica para o tratamento de resistência a inibidores plaquetários. A invenção também se refere a um método para diagnosticar a resistência ao tratamento com inibidores plaquetários, o referido método compreendendo medição da densidade de ligação de Anexina V sobre plaquetas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57059704P | 2004-05-13 | 2004-05-13 | |
| PCT/EP2005/005024 WO2005113006A2 (en) | 2004-05-13 | 2005-05-10 | Use of dipyridamole for treatment of resistance to platelet inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0511054A true BRPI0511054A (pt) | 2007-11-27 |
Family
ID=34969445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0511054-8A BRPI0511054A (pt) | 2004-05-13 | 2005-05-10 | uso de dipiridamola para o tratamento de resistência a inibidores plaquetários |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090048173A1 (pt) |
| EP (1) | EP1747016A2 (pt) |
| JP (1) | JP2007537184A (pt) |
| KR (1) | KR20070026577A (pt) |
| CN (1) | CN101068570A (pt) |
| AU (1) | AU2005245271A1 (pt) |
| BR (1) | BRPI0511054A (pt) |
| CA (1) | CA2566081A1 (pt) |
| IL (1) | IL179169A0 (pt) |
| MX (1) | MXPA06013157A (pt) |
| RU (1) | RU2006143838A (pt) |
| WO (1) | WO2005113006A2 (pt) |
| ZA (1) | ZA200609058B (pt) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008517974A (ja) * | 2004-10-25 | 2008-05-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗血栓薬と併用しての血栓塞栓性疾患の治療および予防のためのジピリダモールの使用 |
| TWI482772B (zh) * | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| CN103582480B (zh) * | 2011-02-09 | 2016-03-16 | 医药公司 | 治疗肺高压的方法 |
| US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| US20150306281A1 (en) * | 2014-04-28 | 2015-10-29 | Nalini Marie Rajamannan | Devices and methods for inhibiting stenosis, obstruction, or calcification of a native heart valve, stented heart valve or bioprosthesis |
| US10058630B2 (en) | 2012-10-22 | 2018-08-28 | Concievalve, Llc | Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis |
| TW201503900A (zh) * | 2013-07-29 | 2015-02-01 | ren-zheng Lin | 增強治療急性中風之抗血小板藥物之遞送方法及其組合物 |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| WO2015113001A1 (en) * | 2014-01-24 | 2015-07-30 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| JP2018516624A (ja) * | 2015-04-15 | 2018-06-28 | コンシーヴァルブ エルエルシー | 自然心臓弁、ステント装着された心臓弁またはバイオプロテーゼの狭窄、閉塞または石灰化を抑制するためのデバイスおよび方法 |
| CN104965017B (zh) * | 2015-06-17 | 2017-06-16 | 广西师范学院 | 水蛭素抗凝血酶活性的测定方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US77729A (en) * | 1868-05-12 | William hall | ||
| US151534A (en) * | 1874-06-02 | Improvement in | ||
| US175831A (en) * | 1876-04-11 | Improvement in jig-saw attachments | ||
| US176469A (en) * | 1876-04-25 | Improvement in carpet-beaters | ||
| US151595A (en) * | 1874-06-02 | Improvement in hand corn-planters | ||
| US107409A (en) * | 1870-09-13 | Improvement in double-shovel plows | ||
| US183519A (en) * | 1876-10-24 | Improvement in cornice-gutters | ||
| US3031450A (en) * | 1959-04-30 | 1962-04-24 | Thomae Gmbh Dr K | Substituted pyrimido-[5, 4-d]-pyrimidines |
| DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
| DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
| DE3627423A1 (de) * | 1986-08-13 | 1988-02-18 | Thomae Gmbh Dr K | Arzneimittel enthaltend dipyridamol oder mopidamol und o-acetylsalicylsaeure bzw. deren physiologisch vertraegliche salze, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung der thrombusbildung |
| US5256559A (en) * | 1988-03-04 | 1993-10-26 | Biogen, Inc. | Methods and compositions for inhibiting platelet aggregation |
| US5498613A (en) * | 1994-06-07 | 1996-03-12 | The University Of Southern California | Dipyridamole and analogs thereof in preventing adhesion formation |
| FR2728901B1 (fr) * | 1994-12-28 | 1997-03-28 | Sanofi Sa | Derives de phenyl-4-thiazoles substitues, procede pour leur preparation et compositions pharmaceutiques les contenant |
| US6136794A (en) * | 1998-02-02 | 2000-10-24 | Merck & Co., Inc. | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| ATE261934T1 (de) * | 1998-12-16 | 2004-04-15 | Boehringer Ingelheim Pharma | Substituierte aryl- und heteroarylamidinderivate, deren herstellung und deren verwendung als arzneimittel |
| EP1093814A1 (en) | 1999-10-22 | 2001-04-25 | Boehringer Ingelheim Pharma KG | Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders |
| WO2001031052A1 (en) * | 1999-10-25 | 2001-05-03 | Colorado Coagulation Consultants | Thromboxane b2 metabolite and methods for regulating aspirin-related platelet action |
| FR2809181B1 (fr) * | 2000-05-16 | 2002-10-25 | Biocytex | Monoreactif pour le dosage des microparticules plaquettaires |
| US8519005B2 (en) * | 2000-07-27 | 2013-08-27 | Thomas N. Thomas | Compositions and methods to prevent toxicity of antiinflammatory agents and enhance their efficacy |
| WO2002059623A2 (en) * | 2001-01-24 | 2002-08-01 | Sendx Medical, Inc. | Methods for determining platelet activity with antiplatelet compositions |
| DE10300111A1 (de) * | 2003-01-07 | 2004-07-15 | Bayer Healthcare Ag | Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid |
| EP1622621A2 (en) | 2003-04-24 | 2006-02-08 | Boehringer Ingelheim International GmbH | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
-
2005
- 2005-05-10 KR KR1020067026148A patent/KR20070026577A/ko not_active Application Discontinuation
- 2005-05-10 WO PCT/EP2005/005024 patent/WO2005113006A2/en active Application Filing
- 2005-05-10 AU AU2005245271A patent/AU2005245271A1/en not_active Abandoned
- 2005-05-10 RU RU2006143838/14A patent/RU2006143838A/ru not_active Application Discontinuation
- 2005-05-10 EP EP05748279A patent/EP1747016A2/en not_active Withdrawn
- 2005-05-10 BR BRPI0511054-8A patent/BRPI0511054A/pt not_active IP Right Cessation
- 2005-05-10 CA CA002566081A patent/CA2566081A1/en not_active Abandoned
- 2005-05-10 CN CNA2005800236935A patent/CN101068570A/zh active Pending
- 2005-05-10 US US11/568,730 patent/US20090048173A1/en not_active Abandoned
- 2005-05-10 JP JP2007512064A patent/JP2007537184A/ja active Pending
- 2005-05-10 MX MXPA06013157A patent/MXPA06013157A/es not_active Application Discontinuation
-
2006
- 2006-10-31 ZA ZA200609058A patent/ZA200609058B/en unknown
- 2006-11-09 IL IL179169A patent/IL179169A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101068570A (zh) | 2007-11-07 |
| KR20070026577A (ko) | 2007-03-08 |
| JP2007537184A (ja) | 2007-12-20 |
| CA2566081A1 (en) | 2005-12-01 |
| IL179169A0 (en) | 2007-03-08 |
| US20090048173A1 (en) | 2009-02-19 |
| WO2005113006A2 (en) | 2005-12-01 |
| AU2005245271A1 (en) | 2005-12-01 |
| ZA200609058B (en) | 2008-03-26 |
| EP1747016A2 (en) | 2007-01-31 |
| WO2005113006A3 (en) | 2007-02-08 |
| RU2006143838A (ru) | 2008-06-20 |
| MXPA06013157A (es) | 2007-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0511054A (pt) | uso de dipiridamola para o tratamento de resistência a inibidores plaquetários | |
| CY1117476T1 (el) | Ανταγωνιστες συμπληρωματων και οι χρησεις αυτων | |
| CL2007003523A1 (es) | Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer | |
| BRPI0510428A (pt) | composições tópicas de metadona e processos para utilização das mesmas | |
| CL2012003026A1 (es) | Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad. | |
| CL2009000757A1 (es) | Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras. | |
| BRPI0611717A2 (pt) | composto, composiÇço farmacÊutica e uso do composto | |
| BRPI0918337A2 (pt) | composto, composição farmacêutica, método de tratamento, método para tratar uma doença ou condição causada, exacerbada ou resultante de um excesso de plaquetas ou ativação indesejada de plaquetas em um paciente, método para reduzir a contagem de plaquetas circulantes em um paciente e uso | |
| ECSP088503A (es) | COMPUESTOS de LACTAMa y MÉTODOS DE USO DE LOS MISMOS | |
| CY1116064T1 (el) | Συστασεις αναστολεα ddp iv | |
| BRPI0607809A2 (pt) | uso de uma composição compreendendo nanopartìculas, composição e kit | |
| BR112014013377A2 (pt) | filme em multicamada livre de camada de metal com baixo peso superficial | |
| BR112015012366A8 (pt) | antagonistas de cxcr7, uso dos mesmos, composição farmacêutica, bem como métodos para detectar níveis elevados de cxcr7 em uma amostra e para imagear um tumor, órgão, ou tecido | |
| BRPI0921999B8 (pt) | uso de uma quantidade terapeuticamente eficaz de células tronco placentárias | |
| BRPI0706676B8 (pt) | uso de uma solução aquosa com potencial de oxirredução | |
| BR112015020209A2 (pt) | uso de linagliptina em terapia antidiabética de proteção cardíaca e renal | |
| BRPI1103213B8 (pt) | Composição de enxaguatório bucal antimicrobiano com teor alcoólico reduzido à base de óleo essencial bioativo | |
| BRPI0519656A2 (pt) | terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida | |
| BR112016008010A2 (pt) | uso de moléculas de ligação de semaforina-4d para tratamento de aterosclerose | |
| BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
| PA8720801A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento de la depresion | |
| BRPI0506537A (pt) | compostos que se ligam a membranas perturbadas e métodos de uso dos mesmos | |
| BR112013029269A2 (pt) | "combinação farmacêutica para uso na melhora da tolerância à glicose em pacientes com diabetes tipo 2 e o uso da mesma". | |
| CY1114735T1 (el) | Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5 | |
| BRPI0816798A2 (pt) | composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |